OptiNose Overview
- Year Founded
-
2010
- Status
-
Acquired/Merged
- Employees
-
144
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
14
OptiNose General Information
Description
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Contact Information
Website
www.optinose.com(Operating Subsidiary)
Corporate Office
- 777 Township Line Road
- Suite 300
- PA 19067
- United States
Corporate Office
- 777 Township Line Road
- Suite 300
- PA 19067
- United States
OptiNose Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
OptiNose Comparisons
Industry
Financing
Details
OptiNose Competitors (1)
One of OptiNose’s competitors is Lyra Therapeutics, a Formerly VC-backed company based in Watertown, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lyra Therapeutics | Formerly VC-backed | Watertown, MA |
OptiNose Patents
OptiNose Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230285278-A1 | Methods for treating chronic rhinosinusitis | Pending | 06-Mar-2022 | ||
| US-20220296825-A1 | Exhalation delivery system for and method of treating sinus disease | Pending | 04-Oct-2018 | ||
| WO-2020070321-A2 | Exhalation delivery system for and method of treating sinus disease | Inactive | 04-Oct-2018 | ||
| US-10360233-B2 | In-memory key-value store for a multi-model database | Active | 19-Nov-2015 | ||
| US-20170147664-A1 | In-memory key-value store for a multi-model database | Active | 19-Nov-2015 | G06F16/258 |
OptiNose Signals
OptiNose Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
OptiNose FAQs
-
When was OptiNose founded?
OptiNose was founded in 2010.
-
Where is OptiNose headquartered?
OptiNose is headquartered in PA.
-
What is the size of OptiNose?
OptiNose has 144 total employees.
-
What industry is OptiNose in?
OptiNose’s primary industry is Drug Delivery.
-
Is OptiNose a private or public company?
OptiNose is a Private company.
-
What is the current valuation of OptiNose?
The current valuation of OptiNose is .
-
What is OptiNose’s current revenue?
The current revenue for OptiNose is .
-
How much funding has OptiNose raised over time?
OptiNose has raised $664M.
-
Who are OptiNose’s investors?
Avista Healthcare Partners, Entrepreneurs Fund, Fidelity Management & Research Company, Foresite Capital, and IKOS Asset Management are 5 of 10 investors who have invested in OptiNose.
-
Who are OptiNose’s competitors?
Lyra Therapeutics is a competitor of OptiNose.
-
When was OptiNose acquired?
OptiNose was acquired on 21-May-2025.
-
Who acquired OptiNose?
OptiNose was acquired by Paratek Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process